Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.5 USD | -1.75% | -11.76% | -24.87% |
Business Summary
Number of employees: 536
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Oral Small Molecule and Protein Therapeutics
100.0
%
| 271 | 100.0 % | 331 | 100.0 % | +22.37% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
87.0
%
| - | - | 288 | 87.0 % | - |
Non-United States
11.4
%
| - | - | 38 | 11.4 % | - |
Global
1.6
%
| 271 | 100.0 % | 5 | 1.6 % | -98.00% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 06-12-31 |
Anthony Doyle
DFI | Director of Finance/CFO | 44 | 20-04-01 |
Michael Jones
DFI | Director of Finance/CFO | 54 | 10-12-31 |
Ryan Arnold
CTO | Chief Tech/Sci/R&D Officer | - | 22-02-28 |
Helen Thackray
CTO | Chief Tech/Sci/R&D Officer | 55 | 19-09-19 |
Philip George
PRN | Corporate Officer/Principal | - | 22-08-31 |
Corporate Officer/Principal | - | 14-12-31 | |
Charles Gayer
PRN | Corporate Officer/Principal | 53 | 15-07-31 |
Human Resources Officer | - | 18-10-31 | |
Salisa Hauptmann
LAW | General Counsel | - | 20-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Levin
BRD | Director/Board Member | 62 | 20-02-26 |
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 06-12-31 |
Director/Board Member | 60 | 21-07-25 | |
Stephen Aselage
BRD | Director/Board Member | 73 | 19-01-03 |
Director/Board Member | 69 | 11-10-09 | |
Nancy Hutson
CHM | Chairman | 74 | 12-01-19 |
Helen Thackray
CTO | Chief Tech/Sci/R&D Officer | 55 | 19-09-19 |
Steven Galson
BRD | Director/Board Member | 67 | 21-08-31 |
Theresa Heggie
BRD | Director/Board Member | 63 | 18-12-02 |
Amy McKee
BRD | Director/Board Member | 52 | 21-09-19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 206,149,929 | 199,798,093 ( 96.92 %) | 0 | 96.92 % |
Company contact information
BioCryst Pharmaceuticals, Inc.
4505 Emperor Boulevard Suite 200
27703-8457, Durham
+919 859 1302
http://www.biocryst.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.87% | 944M | |
-3.30% | 102B | |
+1.79% | 96.84B | |
-0.44% | 21.48B | |
-18.35% | 20.82B | |
-7.45% | 18.6B | |
-40.31% | 16.81B | |
-26.84% | 13.78B | |
+0.59% | 13.4B | |
+20.86% | 11.06B |
- Stock Market
- Equities
- BCRX Stock
- Company BioCryst Pharmaceuticals, Inc.